Wageningen University and DNASTAR Extend Lasergene Site License Agreement
News Nov 24, 2009
DNASTAR and Wageningen University and Research centre in Wageningen, the Netherlands announced the signing of a broad site license agreement for the use of Lasergene® sequence analysis software developed by DNASTAR.
Under the terms of the site license, all researchers in the Department of Agrotechnology and Food Sciences will have unlimited use of the software for their sequence analysis projects. The site license will include the latest version of Lasergene, v8.1, which provides users with automated virtual MultiSite Gateway cloning capabilities, along with numerous other new features.
Lasergene, a comprehensive sequence analysis software program sold in more than 65 countries worldwide, provides users with tools to perform a wide range of DNA assembly, visualization and analysis operations on data generated by the conventional Sanger sequencing method as well as Next Generation platforms available from Roche 454, Illumina, ABI SOLiD and Helicos. It can also be used in a wide range of protein analysis applications. Additional Lasergene information and Free Trial versions of the software are available.
Bob Steinhauser, DNASTAR’s Director of Marketing stated, “Wageningen UR and DNASTAR have been working together for many years. This is the second department-wide site license for the use of our software at the University. We are extremely pleased that as the activities at the University have grown, DNASTAR has been able to grow with them. Lasergene’s novel features, broad applications base and constant updating with new Features, makes it an excellent sequence analysis platform choice to address present and future genomic research needs.”
Watch: Could Digital Microfluidics Revolutionise Experimentation?News
Technology using 'programmable droplets' could enable automated research on a grand scale.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE